That's what I think anyway, but I'm no scientist. But I'm also convinced it will go to cohort 10 at a higher dose and with any luck that higher dose will be the last increase and cohort 11 will be the end of the trial. Best case in my opinion because it means Kevetrin is safe well into the higher dose considered by Menon to be efficacious, and with the trial ended we can move to the next phase.
Market Data 
Markets 
AI
